Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Prasugrel for Japanese Patients With Ischemic Heart Disease in Long-Term Clinical Practice (PRASFIT-Practice II) - 1-Year Follow-up Results of a Postmarketing Observational Study.

Nakamura M, Kitazono T, Kozuma K, Sekine T, Nakamura S, Shiosakai K, Iizuka T.

Circ J. 2019 Dec 25;84(1):101-108. doi: 10.1253/circj.CJ-19-0645. Epub 2019 Nov 21.

2.

Pharmacokinetics and Bioequivalence of Memantine Tablet and a New Dry Syrup Formulation in Healthy Japanese Males: Two Single-Dose Crossover Studies.

Maekawa Y, Hasegawa S, Ishizuka T, Shiosakai K, Ishizuka H.

Adv Ther. 2019 Oct;36(10):2930-2940. doi: 10.1007/s12325-019-01044-y. Epub 2019 Aug 9.

3.

Effect of DS-8500a, a Novel G Protein-Coupled Receptor 119 Agonist, on the Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Subjects.

Maekawa Y, Furuie H, Kato M, Myobatake Y, Kamiyama E, Watanabe A, Shiosakai K, Taguchi T, Bass R, Zhou J, Dishy V, Warren V, Vashi V, Ishizuka H.

Clin Drug Investig. 2019 Oct;39(10):967-978. doi: 10.1007/s40261-019-00825-1.

PMID:
31321631
4.

Safety and Effectiveness of Edoxaban in Japanese Patients With Venous Thromboembolism - An Interim Analysis of Data From a Japanese Postmarketing Observational Study (ETNA-VTE-Japan).

Nakamura M, Yamada N, Asamura T, Shiosakai K, Uchino K.

Circ J. 2019 May 24;83(6):1394-1404. doi: 10.1253/circj.CJ-18-1362. Epub 2019 May 10.

5.

Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): Three-month interim analysis results.

Yamashita T, Koretsune Y, Ishikawa M, Shiosakai K, Kogure S.

J Arrhythm. 2018 Dec 26;35(1):121-129. doi: 10.1002/joa3.12149. eCollection 2019 Feb.

6.

Prasugrel for Japanese Patients With Ischemic Heart Disease in Long-Term Clinical Practice (PRASFIT-Practice II) - A 3-Month Interim Analysis of a Postmarketing Observational Study.

Nakamura M, Kozuma K, Kitazono T, Iizuka T, Sekine T, Shiosakai K, Usui I, Kogure S.

Circ J. 2019 Feb 25;83(3):637-646. doi: 10.1253/circj.CJ-18-0956. Epub 2019 Jan 24.

7.

Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.

Kato M, Ishizuka H, Taguchi T, Shiosakai K, Kamiyama E, Sata M, Yoshida T.

Adv Ther. 2018 Aug;35(8):1239-1250. doi: 10.1007/s12325-018-0739-4. Epub 2018 Jul 2.

PMID:
29968010
8.

Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate in the 2016/17 Japanese influenza season; comparison with the 2011/12 to 2015/16 seasons.

Ikematsu H, Kawai N, Iwaki N, Kashiwagi S, Ishikawa Y, Yamaguchi H, Shiosakai K.

J Infect Chemother. 2018 Sep;24(9):718-724. doi: 10.1016/j.jiac.2018.04.013. Epub 2018 Jun 1.

9.

In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2016-17 season: Comparison with the 2010-11 to 2015-16 seasons.

Ikematsu H, Kawai N, Iwaki N, Kashiwagi S, Ishikawa Y, Yamaguchi H, Shiosakai K.

J Infect Chemother. 2018 Sep;24(9):707-712. doi: 10.1016/j.jiac.2018.04.009. Epub 2018 May 11.

PMID:
29759897
10.

G protein-coupled receptor 119 agonist DS-8500a effects on pancreatic β-cells in Japanese type 2 diabetes mellitus patients.

Watada H, Shiramoto M, Irie S, Terauchi Y, Yamada Y, Shiosakai K, Myobatake Y, Taguchi T.

J Diabetes Investig. 2019 Jan;10(1):84-93. doi: 10.1111/jdi.12849. Epub 2018 May 4.

11.

Efficacy and safety of the G protein-coupled receptor 119 agonist DS-8500a in Japanese type 2 diabetes mellitus patients with inadequate glycemic control on sitagliptin: A phase 2 randomized placebo-controlled study.

Terauchi Y, Yamada Y, Watada H, Nakatsuka Y, Shiosakai K, Washio T, Taguchi T.

J Diabetes Investig. 2018 Nov;9(6):1333-1341. doi: 10.1111/jdi.12846. Epub 2018 May 24.

12.

Safety and Pharmacokinetics of DS-8500a, a Novel GPR119 Agonist, After Multiple Oral Doses in Healthy Japanese Males.

Kato M, Furuie H, Kamiyama E, Shiosakai K, Yoshihara K, Taguchi T.

Clin Drug Investig. 2018 Jun;38(6):519-525. doi: 10.1007/s40261-018-0633-5.

PMID:
29582248
13.

Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study.

Yamada Y, Terauchi Y, Watada H, Nakatsuka Y, Shiosakai K, Washio T, Taguchi T.

Adv Ther. 2018 Mar;35(3):367-381. doi: 10.1007/s12325-018-0668-2. Epub 2018 Feb 27.

14.

Glucose-lowering effects and safety of DS-8500a, a G protein-coupled receptor 119 agonist, in Japanese patients with type 2 diabetes: results of a randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase II study.

Inagaki N, Chou HS, Tsukiyama S, Washio T, Shiosakai K, Nakatsuka Y, Taguchi T.

BMJ Open Diabetes Res Care. 2017 Sep 29;5(1):e000424. doi: 10.1136/bmjdrc-2017-000424. eCollection 2017.

15.

Heart rate control by carvedilol in Japanese patients with chronic atrial fibrillation: The AF Carvedilol study.

Inoue H, Atarashi H, Okumura K, Yamashita T, Fukuzawa M, Shiosakai K, Kimura T.

J Cardiol. 2017 Jan;69(1):293-301. doi: 10.1016/j.jjcc.2016.05.012. Epub 2016 Jun 28.

16.

[Multicenter trial for optimization of bolus tracking settings and contrast material injection protocol in arterial dominant phase of dynamic computed tomography for diagnosis of hepatocellular carcinoma].

Yoshikawa S, Okada M, Kondo H, Sou H, Murakami T, Kanematsu M, Ichikawa T, Hayakawa A, Shiosakai K, Awai K, Yoshimitsu K, Yamashita Y.

Nihon Hoshasen Gijutsu Gakkai Zasshi. 2014 Aug;70(8):805-13. Japanese.

17.

Spread of viral infection to family members from influenza patients treated with a neuraminidase inhibitor.

Nakano T, Shiosakai K.

J Infect Chemother. 2014 Jul;20(7):401-6. doi: 10.1016/j.jiac.2014.01.012. Epub 2014 Apr 29.

PMID:
24787736
18.

Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan.

Nakamura Y, Kitamura S, Homma A, Shiosakai K, Matsui D.

Expert Opin Pharmacother. 2014 May;15(7):913-25. doi: 10.1517/14656566.2014.902446. Epub 2014 Mar 27.

19.

The efficacy of contrast protocol in hepatic dynamic computed tomography: multicenter prospective study in community hospitals.

Okada M, Kondo H, Sou H, Murakami T, Kanematsu M, Ichikawa T, Yoshikawa S, Shiosakai K, Hayakawa A, Awai K, Yoshimitsu K, Yamashita Y.

Springerplus. 2013 Jul 31;2:367. doi: 10.1186/2193-1801-2-367. eCollection 2013.

20.

Recommended iodine dose for multiphasic contrast-enhanced mutidetector-row computed tomography imaging of liver for assessing hypervascular hepatocellular carcinoma: multicenter prospective study in 77 general hospitals in Japan.

Ichikawa T, Okada M, Kondo H, Sou H, Murakami T, Kanematsu M, Yoshikawa S, Shiosakai K, Hayakawa A, Awai K, Yoshimitsu K, Yamashita Y.

Acad Radiol. 2013 Sep;20(9):1130-6. doi: 10.1016/j.acra.2013.05.003.

PMID:
23931427

Supplemental Content

Loading ...
Support Center